We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Lineage Cell Therapeutics Inc (LCTX) NPV

Sell:$0.50 Buy:$0.50 Change: $0.033 (6.13%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$0.50
Buy:$0.50
Change: $0.033 (6.13%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$0.50
Buy:$0.50
Change: $0.033 (6.13%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.

Contact details

Address:
2173 Salk Avenue, Suite 200
CARLSBAD
92008
United States
Telephone:
+1 (510) 5213390
Website:
https://lineagecell.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
LCTX
ISIN:
US53566P1093
Market cap:
$118.58 million
Shares in issue:
220.42 million
Sector:
Biotechnology
Exchange:
-
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Brian Culley
    Chief Executive Officer, Director
  • Jill Howe
    Chief Financial Officer
  • George Samuel
    General Counsel, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.